CUR - Neuralstem, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5525
+0.0817 (+17.35%)
At close: 4:00PM EST

0.5600 +0.01 (1.36%)
After hours: 5:43PM EST

Stock chart is not supported by your current browser
Previous Close0.4708
Open0.5000
Bid0.5200 x 3000
Ask0.5600 x 1400
Day's Range0.4701 - 0.5600
52 Week Range0.2500 - 2.0500
Volume499,444
Avg. Volume162,708
Market Cap10.058M
Beta (3Y Monthly)2.66
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Germantown biotech faces stock delisting threat
    American City Business Journals2 months ago

    Germantown biotech faces stock delisting threat

    Germantown-based Neuralstem Inc. has been put on notice that its stock could be delisted from the Nasdaq if the company can’t raise its share price above $1 continually within the next six months. The stem cell therapy company said it intends to continue actively monitoring its common stock price and will consider options to boost its value. To return to compliance, Neuralstem stock must close at or above $1 per share for at least 10 consecutive days, though the company could file for an extension or appeal.

  • How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?
    Simply Wall St.3 months ago

    How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?

    Neuralstem Inc (NASDAQ:CUR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CUR will Read More...

  • Should You Have Neuralstem Inc’s (NASDAQ:CUR) In Your Portfolio?
    Simply Wall St.5 months ago

    Should You Have Neuralstem Inc’s (NASDAQ:CUR) In Your Portfolio?

    If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...

  • Benzinga7 months ago

    Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...